As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > BUSINESS
BUSINESS
- MTPC Introduces 3-level Priority for Priority Products
October 25, 2011
- “Sales of Teribone Can Reach ¥10 Bil.”: President Asano of Asahi Kasei Pharma
October 25, 2011
- Mochida Upwardly Revises Business Forecasts for 1st Half of FY2012
October 25, 2011
- Biggest Challenge Is Decline in R&D Productivity: President Hasegawa of Takeda
October 25, 2011
- IBL Signs Licensing Contact with US Firm for Lung Cancer Type Identifying Antibody
October 25, 2011
- Daiichi Sankyo, AZ Apply for Additional Indication for Nexium for Prevention of GU, DU in Patients Given Low-Dose Aspirin
October 25, 2011
- Pfizer Japan to Split Up Domestic Manufacturing Sector to Establish New Company
October 25, 2011
- Top Drug Makers Poised to Announce 1st-Half Results: Patent Expirations Could Have Big Impact
October 25, 2011
- CMIC, Medipal Set Up Joint Venture for Orphan Drugs, Develop Alliance Model
October 24, 2011
- Sales Remain Unchanged due to Domestic Market Slump Affected by Quake: Chugai Jan-Sep 2011
October 24, 2011
- MSD, Mylan Terminate Promotional Contract for Lipovas and Renivase
October 24, 2011
- Astellas Recalls Tacrolimus in Japan, Europe After Dissolution Test Standards Unmet
October 24, 2011
- SymBio’s Bendamustine Gets NDA Approval in Taiwan
October 24, 2011
- US Baxter International Initiates PIII Clinical Trial for Blood Disorder Treatment Drug
October 24, 2011
- Otsuka Confirms Efficacy of Rotigotine for RLS in Domestic PIII Clinical Study
October 21, 2011
- Ono Upwardly Revises Sales Forecast Due to Main Product Growth
October 21, 2011
- Abbott to Separate into 2 Companies
October 21, 2011
- Chugai Tops Patent Asset Rankings, Teijin Jumps to Second Place
October 21, 2011
- No. of Latuda Prescriptions to Potentially Exceed Forecast: Nomura Securities
October 21, 2011
- Takeda Positions “Enbrel MRs” in Boosted Cooperation Efforts with Pfizer
October 20, 2011
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…